Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Leases (2023 - 2026)

Contineum Therapeutics' Current Leases history spans 4 years, with the latest figure at $2.3 million for Q1 2026.

  • Quarterly Current Leases rose 58.28% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Mar 2026, up 58.28% year-over-year, with the annual reading at $2.3 million for FY2025, 61.23% up from the prior year.
  • Current Leases came in at $2.3 million for Q1 2026, down from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.3 million in Q4 2025 to a low of $464000.0 in Q4 2023.
  • The 4-year median for Current Leases is $1.5 million (2024), against an average of $1.3 million.
  • Year-over-year, Current Leases surged 212.93% in 2024 and then surged 58.28% in 2026.
  • Contineum Therapeutics' Current Leases stood at $464000.0 in 2023, then soared by 212.93% to $1.5 million in 2024, then surged by 61.23% to $2.3 million in 2025, then dropped by 1.62% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Current Leases are $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $1.5 million (Q3 2025).